vs
Side-by-side financial comparison of BingEx Ltd (FLX) and PTC THERAPEUTICS, INC. (PTCT). Click either name above to swap in a different company.
PTC THERAPEUTICS, INC. is the larger business by last-quarter revenue ($164.7M vs $143.2M, roughly 1.1× BingEx Ltd). BingEx Ltd runs the higher net margin — 2.2% vs -82.0%, a 84.2% gap on every dollar of revenue.
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
FLX vs PTCT — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $143.2M | $164.7M |
| Net Profit | $3.2M | $-135.0M |
| Gross Margin | 10.8% | — |
| Operating Margin | — | -43.3% |
| Net Margin | 2.2% | -82.0% |
| Revenue YoY | — | -22.7% |
| Net Profit YoY | — | -104.8% |
| EPS (diluted) | — | $-1.63 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $143.2M | — | ||
| Q4 25 | — | $164.7M | ||
| Q3 25 | $141.2M | $211.0M | ||
| Q2 25 | $143.0M | $178.9M | ||
| Q1 25 | $141.0M | $1.2B | ||
| Q4 24 | — | $213.2M | ||
| Q3 24 | $164.6M | $196.8M | ||
| Q2 24 | — | $186.7M |
| Q1 26 | $3.2M | — | ||
| Q4 25 | — | $-135.0M | ||
| Q3 25 | $6.1M | $15.9M | ||
| Q2 25 | $7.5M | $-64.8M | ||
| Q1 25 | $27.6M | $866.6M | ||
| Q4 24 | — | $-65.9M | ||
| Q3 24 | $3.4M | $-106.7M | ||
| Q2 24 | — | $-99.2M |
| Q1 26 | 10.8% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 11.1% | — | ||
| Q2 25 | 12.0% | — | ||
| Q1 25 | 10.0% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 11.3% | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | -43.3% | ||
| Q3 25 | 1.4% | 1.4% | ||
| Q2 25 | 1.9% | -19.5% | ||
| Q1 25 | — | 82.5% | ||
| Q4 24 | — | -76.2% | ||
| Q3 24 | 4.0% | -27.7% | ||
| Q2 24 | — | -21.5% |
| Q1 26 | 2.2% | — | ||
| Q4 25 | — | -82.0% | ||
| Q3 25 | 4.4% | 7.5% | ||
| Q2 25 | 5.2% | -36.3% | ||
| Q1 25 | 19.6% | 73.7% | ||
| Q4 24 | — | -30.9% | ||
| Q3 24 | 2.1% | -54.2% | ||
| Q2 24 | — | -53.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | $-1.63 | ||
| Q3 25 | — | $0.20 | ||
| Q2 25 | — | $-0.83 | ||
| Q1 25 | — | $10.04 | ||
| Q4 24 | — | $-0.85 | ||
| Q3 24 | — | $-1.39 | ||
| Q2 24 | — | $-1.29 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $561.1M | $1.9B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $-205.3M |
| Total Assets | $1.3B | $2.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $561.1M | — | ||
| Q4 25 | — | $1.9B | ||
| Q3 25 | $628.6M | $1.7B | ||
| Q2 25 | $499.4M | $2.0B | ||
| Q1 25 | $592.4M | $2.0B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | $517.4M | $1.0B | ||
| Q2 24 | — | $1.1B |
| Q1 26 | — | — | ||
| Q4 25 | — | $-205.3M | ||
| Q3 25 | — | $-155.8M | ||
| Q2 25 | — | $-206.5M | ||
| Q1 25 | — | $-185.8M | ||
| Q4 24 | — | $-1.1B | ||
| Q3 24 | — | $-1.1B | ||
| Q2 24 | — | $-980.2M |
| Q1 26 | $1.3B | — | ||
| Q4 25 | — | $2.9B | ||
| Q3 25 | $1.3B | $2.6B | ||
| Q2 25 | $1.2B | $2.6B | ||
| Q1 25 | $1.2B | $2.7B | ||
| Q4 24 | — | $1.7B | ||
| Q3 24 | $926.8M | $1.8B | ||
| Q2 24 | — | $1.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-34.3M |
| Free Cash FlowOCF − Capex | — | $-36.6M |
| FCF MarginFCF / Revenue | — | -22.3% |
| Capex IntensityCapex / Revenue | — | 1.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $702.3M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $-34.3M | ||
| Q3 25 | — | $-66.3M | ||
| Q2 25 | — | $-58.3M | ||
| Q1 25 | — | $870.1M | ||
| Q4 24 | — | $-30.0M | ||
| Q3 24 | — | $-77.0M | ||
| Q2 24 | — | $-71.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | $-36.6M | ||
| Q3 25 | — | $-69.7M | ||
| Q2 25 | — | $-59.6M | ||
| Q1 25 | — | $868.4M | ||
| Q4 24 | — | $-33.8M | ||
| Q3 24 | — | $-77.5M | ||
| Q2 24 | — | $-78.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | -22.3% | ||
| Q3 25 | — | -33.1% | ||
| Q2 25 | — | -33.3% | ||
| Q1 25 | — | 73.8% | ||
| Q4 24 | — | -15.8% | ||
| Q3 24 | — | -39.4% | ||
| Q2 24 | — | -42.2% |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.4% | ||
| Q3 25 | — | 1.6% | ||
| Q2 25 | — | 0.7% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 1.8% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 4.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | -4.17× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.00× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
